Autogene Cevumeran plus Atezolizumab and mFolfirinox vs mFolfirinox alone (Pancreatic Cancer) - Clinical Trial

Email to Participate

¿Cuál es el Propósito de este estudio?

We are doing this study to compare 2 different regimens for treating pancreatic cancer after surgery. We what find out how well patients do after they get a combination of the drugs cevumeran, atezolizumab, and mFOLFIRINOX compared to just getting mFOLFIRINOX alone. Cevumeran is an experimental drug that is made from your own cells that are obtained from blood and tissue samples. It is designed to activate your immune system against cancer cells in your body.

¿Cuál es la Condición que se está estudiando?

Cáncer de páncreas

¿Quién puede participar en el Estudio?

Adults ages 18+ who:

Are diagnosed with pancreatic cancer
Are able to have surgery to remove the cancer

For more information about who can join this study, contact the study team at jennifer.gallagher@duke.edu.

Grupo etario

Adultos

¿Qué Implica?

Si decide unirse a este estudio, recibirá una asignación aleatoria (como lanzar una moneda al aire) para:

Get the combination of autogene cevumeran plus atezolizumab and mFOLFIRINOX; OR
Get mFOLFIRINOX alone

Detalles del Estudio

Título Completo

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF ADJUVANT AUTOGENE CEVUMERAN PLUS ATEZOLIZUMAB AND mFOLFIRINOX VERSUS mFOLFIRINOX ALONE IN PATIENTS WITH RESECTED PANCREATIC DUCTAL ADENOCARCINOMA

Investigador Principal